Published in World J Surg on March 01, 2005
Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A (2008) 2.22
Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. World J Surg (2006) 0.95
Novel cell lines established from pediatric brain tumors. J Neurooncol (2011) 0.92
Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene (2008) 0.92
Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin Cancer Biol (2008) 0.90
β-Arrestin1 and distinct CXCR4 structures are required for stromal derived factor-1 to downregulate CXCR4 cell-surface levels in neuroblastoma. Mol Pharmacol (2014) 0.82
Generation and characterization of novel local and metastatic human neuroblastoma variants. Neoplasia (2008) 0.82
Effect of retinoic acid and delta-like 1 homologue (DLK1) on differentiation in neuroblastoma. Nutr Res Pract (2010) 0.80
Targeting focal adhesion kinase in neuroblastoma. Anticancer Agents Med Chem (2010) 0.75
Neonatal tumours. Pediatr Surg Int (2013) 0.75
Polyphyllin D, a steroidal saponin in Paris polyphylla, induces apoptosis and necroptosis cell death of neuroblastoma cells. Pediatr Surg Int (2017) 0.75
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol (1993) 10.87
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Molecular biology of neuroblastoma. J Clin Oncol (1999) 6.54
The International Neuroblastoma Pathology Classification (the Shimada system). Cancer (1999) 6.42
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A (2000) 6.30
Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J (1997) 4.99
N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J (2001) 4.85
Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature (1985) 4.31
Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst (1984) 4.01
A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer (1971) 3.71
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991) 3.16
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03
A population-based study of the usefulness of screening for neuroblastoma. Lancet (1997) 2.92
The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J (1998) 2.86
MCM proteins: evolution, properties, and role in DNA replication. Biochim Biophys Acta (1998) 2.73
Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci (2001) 2.66
Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med (1996) 2.66
Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res (1999) 2.49
A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol (2001) 2.33
Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet (2000) 2.19
Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med (1984) 2.09
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol (2000) 2.02
Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A (1984) 1.99
Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol (1994) 1.92
Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res (2002) 1.84
Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol (1998) 1.84
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med (1996) 1.70
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol (1997) 1.59
Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res (1995) 1.45
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol (2000) 1.40
Myc oncogenes: the enigmatic family. Biochem J (1996) 1.32
Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer (2000) 1.32
The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer (1997) 1.30
Neuroblastoma: a clinical challenge and biologic puzzle. CA Cancer J Clin (1995) 1.30
Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res (1994) 1.27
Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res (2003) 1.24
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res (2002) 1.23
A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol (1992) 1.20
Cloning and characterization of human MCM7 promoter. Gene (1998) 1.18
Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol (1998) 1.12
CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg (2004) 1.12
DNA binding by N- and L-Myc proteins. Oncogene (1993) 1.11
The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol (1994) 1.10
Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer (1995) 1.09
Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group "Survey". Med Pediatr Oncol (2001) 1.07
Experience with International Neuroblastoma Staging System and Pathology Classification. Br J Cancer (2002) 1.06
Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst (1997) 1.05
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol (1998) 1.01
Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer (1980) 0.99
Analysis of nerve growth factor receptor expression in human neuroblastoma and neuroepithelioma cell lines. Cancer Res (1989) 0.96
Direct recruitment of N-myc to target gene promoters. Mol Carcinog (2000) 0.95
Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene (2003) 0.95
Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer (2003) 0.92
Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J Biol Chem (1999) 0.92
Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosomes Cancer (2000) 0.89
Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg (1995) 0.89
CD44--a new prognostic marker for neuroblastoma. N Engl J Med (1993) 0.88
Differential patterns of DNA binding by myc and max proteins. Proc Natl Acad Sci U S A (1993) 0.88
Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett (2003) 0.83
One hundred neuroblastomas detected through a mass screening system in Japan. Cancer (1994) 0.81
Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases. J Pediatr (1983) 0.80
Neonatal neuroblastoma: incidence and clinical outcome. Med Pediatr Oncol (2003) 0.80
MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells. Exp Cell Res (2000) 0.79
Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group. Hum Pathol (1988) 0.79
Neuroblastoma in the first year of life: clinical and biologic factors influencing outcome. Semin Pediatr Surg (1993) 0.79
Absence of functional CD44 hyaluronan receptor on human NMYC-amplified neuroblastoma cells. Cancer Res (1997) 0.78
10 years' neuroblastoma screening in Europe: preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE). Eur J Cancer (1998) 0.76
Characterization of the gene expression profile of neuroblastoma cell line IMR-5 using serial analysis of gene expression. Cancer Lett (2003) 0.75
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol (2008) 2.94
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A (2005) 2.19
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 1.89
Needle decompression to avoid tension pneumoperitoneum and hemodynamic compromise after pneumatic reduction of pediatric intussusception. Pediatr Radiol (2013) 1.56
Needle core vs open biopsy for diagnosis of intermediate- and high-risk neuroblastoma in children. J Pediatr Surg (2012) 1.51
Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol (2011) 1.48
Acquired von Willebrand syndrome and Wilms tumor: not always benign. Pediatr Blood Cancer (2009) 1.45
Renal tumors in infants less than 6 months of age. J Pediatr Surg (2004) 1.44
G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res (2013) 1.41
Severe dysplasia in children with familial adenomatous polyposis: rare or simply overlooked? J Pediatr Surg (2006) 1.38
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther (2006) 1.34
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res (2002) 1.23
Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression. J Biol Chem (2008) 1.23
Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther (2009) 1.22
Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med (2014) 1.21
CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg (2004) 1.12
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia (2009) 1.07
TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis (2013) 1.06
Permanent hemodialysis vascular access survival in children and adolescents with end-stage renal disease. Kidney Int (2002) 1.04
Imaging accuracy and incidence of Wilms' and non-Wilms' renal tumors in children. J Pediatr Surg (2008) 1.00
Surgery for peptic ulcer disease in children in the post-histamine2-blocker era. J Pediatr Surg (2005) 0.99
Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res (2008) 0.99
Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther (2005) 0.99
Primary malignant pancreatic neoplasms in children and adolescents: a 20 year experience. J Pediatr Surg (2012) 0.99
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Curr Drug Targets (2014) 0.98
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis (2011) 0.96
Unusually early presentation of small-bowel adenocarcinoma in a patient with Peutz-Jeghers syndrome. J Pediatr Hematol Oncol (2013) 0.95
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol (2009) 0.93
A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials (2012) 0.92
mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis (2015) 0.90
MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Res (2007) 0.90
MKP-8, a novel MAPK phosphatase that inhibits p38 kinase. Biochem Biophys Res Commun (2005) 0.90
Prenatal presentation and outcome of children with pleuropulmonary blastoma. J Pediatr Surg (2006) 0.88
MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett (2005) 0.86
Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res (2013) 0.86
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol (2011) 0.84
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res (2005) 0.82
Traumatic hepatic artery laceration managed by transarterial embolization in a pediatric patient. J Pediatr Surg (2013) 0.82
Pediatric oncology: G-CSF counteracts chemotherapy toxicity in neuroblastoma. Nat Rev Clin Oncol (2010) 0.81
Increased complication rates associated with Port-a-Cath placement in pediatric patients: location matters. J Pediatr Surg (2013) 0.80
Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma. J Pediatr Surg (2007) 0.80
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol (2004) 0.80
MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Cell Cycle (2005) 0.80
The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma. Pediatr Blood Cancer (2005) 0.79
Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs (2004) 0.78
Transumbilical pyloromyotomy with umbilicoplasty provides ease of access and excellent cosmetic results. J Pediatr Surg (2008) 0.77
Relapse surveillance in AFP-positive hepatoblastoma: re-evaluating the role of imaging. Pediatr Radiol (2014) 0.76
Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma. Mol Cancer Ther (2009) 0.76
An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura. J Pediatr Surg (2012) 0.76
Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother Pharmacol (2006) 0.76
Retroperitoneal hemangioma of infancy. J Pediatr Surg (2006) 0.75
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol (2008) 0.75
A retrospective study of multimodal analgesic treatment after laparoscopic appendectomy in children. Paediatr Anaesth (2013) 0.75
Extrarenal Wilms tumor: a case report and review of the literature. J Pediatr Surg (2013) 0.75
Mediastinal lymphangioma presenting as an acute epidural hematoma. J Neurosurg Pediatr (2008) 0.75
Video-assisted thorascopic repair of a subarachnoid-pleural fistula in a child after thoracic tumor resection: technical note. Spine (Phila Pa 1976) (2010) 0.75
Complications related to the Nuss procedure: minimizing risk with operative technique. J Pediatr Surg (2013) 0.75
Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol (2017) 0.75
Mutations of PTCH1, MLL2, and MLL3 are not frequent events in hepatoblastoma. Pediatr Blood Cancer (2011) 0.75